VYNE Therapeutics Inc (VYNE) - היקף יתרות המזומנים של החברה

VYNE Therapeutics focuses on the long-term implementation of pan-BET inhibitors for the therapy of dermatological pathologies. Production and research have been outsourced to third-party contractors to optimize logistics. The company's cash assets demonstrate liquidity dynamics, where the current level equals 0.03. Currently, the company operates on previously raised investments, as the drug testing stage has not yet generated stable operating income.
פילוחים אנליטיים של חברת VYNE Therapeutics

Defensive assets are selected based on the criterion of high financial autonomy. VYNE Therapeutics (VYNE) confirms this status, leveraging its position as a recognized leader in immunodermatology and the trust of the medical community. This metric aggregates all liquid assets, determining the business's ability to fund R&D without external loans. By analyzing the cash balance, an investor assesses the real resource potential and the risks of cash flow gaps. A sufficient liquidity reserve guarantees the stability of new drug development.